and delivers a new drug. ''Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease,'' the FDA said yesterday in a statement. The patch delivers a drug called rotigotine to treat the fatal and incurable brain disease.
Rotigotine is similar to other drugs used to treat Parkinson's -- it is a so-called dopamine agonist, which provides more dopamine, a message-carrying chemical, to the brain.
Parkinson's is caused when dopamine-producing cells are mistakenly destroyed in the brain. It is marked by worsening tremors and paralysis.
There is no cure and all treatments eventually stop working.
The Neupro patch is replaced every 24 hours and provides a continuous dose of the drug.
''The most common side effects for Neupro included skin reactions at the patch site, dizziness, nausea, vomiting, drowsiness and insomnia, most of which are typical of this class of drugs,'' the FDA said.
According to the Parkinson's Action Network, more than one million Americans have Parkinson's disease and 60,000 new cases are diagnosed each year.
-- (Reuters) -- 10FN37.XML
Viewer's Comment |
Comments Not Available |
|
| |
Pondy to implement Goondas Act in December
Three commit suicide
Stage set for U\'Khand foundation day tomorrow
Student crushed to death by tanker
Chinars turn into blaze, present a magnificent look in Kashmir
India to exit from fiscal stimulus next year; growth at 7 pc in FY11
SC to examine foreign law firms related income tax issue
Centre decides to take action against corrupt officials
